

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

03 FEB 24 PM 4:03

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name <u>Genzyme Corporation</u>			
2. Address <input type="checkbox"/> Check if different than previously reported <u>1020 Nineteenth Street, NW, Suite 550, Washington, DC 20036</u>			
3. Principal Place of Business (if different from line 2) City: <u>Cambridge</u> State/Zip (or Country) <u>MA 02139</u>			
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
<u>Mary McGrane</u>	<u>(202) 296-3280</u>		<u>16054-12</u>
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # <u>30257000</u>


TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____

11. No Lobbying **INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ <u>600,000.00</u> Expenses (nearest \$)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033 Internal Revenue Code</p> <p><input checked="" type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code</p>
---	---

Signature 

Printed Name and Title Mary McGrane, Senior Vice President, Government Relations

LD-2 (REV. 6/98)

P/

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

- a) Support Medicare coverage of oral phosphate-binding drugs
 H.R. 3246 – “To amend title XVIII of the Social Security Act to provide for coverage under the Medicare Program of **oral** drugs to reduce serum **phosphate** levels in patients with end-stage renal disease.”
 S. 1304 – “A bill to amend title XVIII of the Social Security Act to provide for coverage under the medic program of **oral** drugs to reduce serum **phosphate** levels in dialysis patients with end-stage renal disease.”
- b) Medicare Prescription Drug Benefit:
 S. 10 – “Medicare Prescription Drug Coverage Act of 2001”
 S. 357 – “Medicare Preservation and Improvement Act of 2001”
 S. 358 – “Medicare Prescription Drug and Modernization Act of 2001”
 S. 812 – “Greater Access to Affordable Pharmaceuticals Act of 2002”—Senate Floor Amendments under S. 812 related to Medicare
 S. 1135 – “Medicare Reform Act of 2001”
 S. 2729 – “21st Century Medicare Act”
 S. 2625 – “Medicare Outpatient Prescription Drug Act of 2002”
 H.R. 4954 – “Medicare Modernization and Prescription Drug Act of 2002”
- c) Support modification of Medicare hospital prospective payment system for hospital outpatient department
- d) Medicare payment system for physician-administered drugs

17. House (s) of Congress and Federal agencies contacted

Check if None

- a) United States Senate
United States House of Representatives
- b) United States Senate
United States House of Representatives
Executive Office of the President
Department of Health and Human Services
- c) United States Senate
United States House of Representatives
Department of Health and Human Services
Center for Medicare and Medicaid Services
Office of Management and Budget
- d) United States Senate
United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<u>Mary McGrane</u>	
<u>Sara Froelich</u>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____

Date 14 February 2003

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

- a) Federal oversight and regulation of gene therapy research and protection of human research subjects
H.R. 4697 – “Human research Subject Protections of 2002”
- b) S. 1379 – “Rare Diseases Act of 2001”
H.R. 4013 - “Rare Diseases Act of 2002”
H.R. 4014 – “Rare Diseases Orphan Product Development Act of 2002”

17. House (s) of Congress and Federal agencies contacted

Check if None

- a) United States Senate
United States House of Representatives
- b) United States Senate
United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary McGrane	
Sara Froelich	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date 14 February 2003

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the regi: engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** p information as requested. Attach additional page(s) as needed.

15. General issue area code INS (one per page)

16. Specific lobbying issues

Support provisions prohibiting health plans from labeling FDA-approved products as “experimental or “inve
H.R. 526 – “Bipartisan Patient Protection Act of 2001” – Section 118(b)
H.R. 2563 - “Bipartisan Patient Protection Act of 2001” – Section 118(b)
S. 283 - “Bipartisan Patient Protection Act of 2001” – Section 118(b)
S. 872 - “Bipartisan Patient Protection Act of 2001” – Section 118(b)
S. 1052 - “Bipartisan Patient Protection Act of 2001” – Section 118(b)

17. House (s) of Congress and Federal agencies contacted

Check if None

United States Senate
United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary McGrane	
Sara Froelich	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date 14 February 2003

Printed Name and Title Mary McGrane, Senior Vice President, Government Relations

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

Oppose creation of a system to approve generic biologics

S. 812 – “Greater Access to Affordable Pharmaceuticals Act of 2001”

H.R. 1862 – “Greater Access to Affordable Pharmaceuticals Act of 2001”

S. 2801/H.R. 5263 – “The Agriculture, Rural Development, Food and Drug Administration (FDA) and Related Appropriations Act of 2002

17. House (s) of Congress and Federal agencies contacted

Check if None

United States Senate
United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary McGrane	
Sara Froelich	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date 14 February 2003

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the regi engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, p information as requested. Attach additional page(s) as needed.**

15. General issue area code PHA (one per page)

16. Specific lobbying issues

H.R. 3580 – Medical Devices Amendments of 2001”

17. House (s) of Congress and Federal agencies contacted

Check if None

United States Senate
United States House of Representatives
Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary McGrane	
Sara Froelich	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date 14 February 2003

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the regi: engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** p information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

- Support expansion of the orphan drug tax credit
 - S. 1052 – “Bipartisan Patient Protection Act”
 - H.R. 1298/S. 1341 – “The Orphan Drug Tax Credit Act of 2001”
 - H.R. 1836 – “Economic Growth and Tax Relief Reconciliation Act of 2001”
 - H.R. 2563 – “Bipartisan Patient Protection Act”
 - H.R. 4946 – Improving Access to Long-term Care Act of 2002”

17. House (s) of Congress and Federal agencies contacted

Check if None


United States Senate
United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary McGrane	
Sara Froelich	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature  Date 14 February 2003

